Gastrointestinal Stromal Tumors
Diagnostic intervals were prolonged in nearly half of patients with GIST, particularly in female patients and those with small‑intestinal tumors or mid‑sized tumors.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.
Related signals
- Disproportionality analysis of adverse events associated with tyrosine kinase inhibitors in gastrointestinal stromal tumors in the FDA adverse event reporting system
- Review of Genomic Testing and SDH Deficiency in Gastrointestinal Stromal Tumors: Getting to the GIST
- Molecular Tailored Therapeutic Options for Advanced Gastrointestinal Stromal Tumors (GISTs): Current Practice and Future Perspectives
- Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach
- UK clinical practice guidelines for the management of gastrointestinal stromal tumours (GIST)